First COVID-19 vaccine given green light for Phase I trial in China
CanSino Biologics' Ad5-nCoV vaccine, a potential COVID-19 prophylactic, has been approved for study in a Phase I clinical trial in China.
List view / Grid view
News
CBD could reduce behavioural problems in children with intellectual disability
A new study has shown that in children and adolescents with an intellectual disability, cannabidiol (CBD) reduced severe behavioural problems.
Gilead prices remdesivir at $2,340 per patient for developed countries
Gilead has announced that the potential COVID-19 drug remdesivir will cost $390 per vial for developed countries, with treatment courses costing $2,340 per patient.
FDA approves new administration route for Phesgo to treat breast cancer
The FDA has given approval to Phesgo for injection under the skin to treat HER2-positive breast cancer, meaning it can be administered at home by a healthcare professional.
First COVID-19 vaccine clinical trial approved in India
Indian authorities have given the green light to test Bharat Biotech's COVID-19 vaccine in Phase I and Phase II clinical trials.
Common cancer treatments do not worsen COVID-19 infection, study finds
A study has found that chemotherapy and surgery do not correlate with worse COVID-19 outcomes for cancer patients, whereas taking immune checkpoint inhibitors does.
NICE does not recommend Novartis’ siponimod for secondary progressive MS
NICE has decided to not recommend Mayzent (siponimod) for use on the NHS as a secondary progressive multiple sclerosis treatment because its clinical trial did not directly compare it to interferon beta-1b.
Kymab wins UK court case against Regeneron’s patent claims
The UK Supreme Court has ruled that Regeneron's patent claim regarding genetically modified mice against Kymab are invalid.
Moderna and Catalent to collaborate on COVID-19 vaccine manufacture
Catalent's biologics facility will conduct large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate.
EMA recommends authorisation for remdesivir to combat COVID-19
The EMA's human medicines committee (CHMP) has recommended a conditional marketing authorisation for Veklury (remdesivir) to treat COVID-19.
Over 2,000 clinical trials currently underway for COVID-19 therapies, finds study
New findings have revealed that over 2,000 clinical trials are being conducted to test COVID-19 therapies while 583 companies are involved in treatment and vaccine development.
Epidyolex (cannabidiol) reclassified as Schedule 5 in UK, relaxing control over drug
GW Pharmaceuticals's Epidyolex (cannabidiol) has been changed from a Schedule 2 drug to a Schedule 5 drug, making it exempt from virtually all controlled drug requirements.
First patient dosed with COVID-19 vaccine using self-amplifying RNA
A Phase I clinical trial to test Imperial College London's COVID-19 vaccine candidate has been initiated, with the first patient dosed.
bioBoaVista manufactures customised media for COVID nasal diagnostic tests using the Flexicon PF7
bioBoaVista showcases its viral transport medium, that can stabilise samples, for efficient nasal tests for the diagnosis of COVID-19.
Consortium established to monitor COVID-19 vaccines after marketing
A new consortium has been formed for the study of COVID-19 vaccines after their approval, to monitor their safety and efficacy.
